News

AVANT BIO participates in Nomic Bio’s $42 Million, oversubscribed Series B Financing Round

Today AVANT BIO announced its participation in Nomic Bio’s Series B financing round, the oversubscribed round brings Nomic’s total raise to $60M.

Founded to make scientists in drug discovery more successful, Nomic has developed nELISA, a next-generation ELISA platform for measuring proteins at scale and at high throughput.  Nomic currently serves over 75 pharma and biotech companies that have collectively profiled more than 400,000 samples to date. To achieve this, Nomic has leveraged the nELISA to build the world’s highest throughput protein profiling service, complete with a versatile and rapid reagent manufacturing platform.

Drug Discovery is an area AVANT BIO closely monitors.  It is a critical bottleneck and cost driver in the development of next generation therapeutics and a unique opportunity for visionary companies developing services an solutions to address them.  We are thrilled to support Nomic as they empower researchers with their cutting edge technology and service offering

Read Nomic Bio’s press release here.

Please follow Nomic Bio on LinkedIn to keep up with their latest news.

Visit Nomic Bio to learn more about their technology.